AB122 Platform Study
Platform Study of AB122 Based Treatments in Patients with Advanced Solid Tumors
Taiho Pharmaceutical Co., Ltd.
917 participants
Jun 1, 2021
INTERVENTIONAL
Conditions
Summary
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.
AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.
AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.
Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.
Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.
Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.
AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04999761